School of Social and Political Science

Background

I am currently Post Graduate Advisor (on course) for research students in STIS. I have previously served as Head of the Science, Technology and Innovation Studies Subject Group (2018-2021); Deputy Director (Research) of the Graduate School of Social and Political Science (2015-2017); Director of the MSc in Management of Bioeconomy, Innovation and Goverance (BIG) (2014-2017); Deputy Director of the Innogen Institute (2014-2017); and Postgraduate Research Advisor (admissions) for STIS (2014-2015), when I also convened the Science, Technology and Innovation Studies Pathway for the Scottish Graduate School of Social Science.

In 2018 I successfully completed the Edinburgh Teaching Award and became a Senior Fellow of the UK Higher Education Authority (SFHEA)

Qualifications

BA (Hons) Humanities and Social Science (Sociology with Philosophy) (MMU 1997)

MA Sociology (University of Leeds 1998)

PhD Sociology (University of Warwick 2004)

Edinburgh Teaching Award/Senior Fellow Higher Education Authority (SFHEA, 2018)

Publications

My ORCID idenitfier is: 0000-0002-0185-6770

Books

Mittra, J. (2016) The New Health Bioeconomy: R&D Policy and Innovation for the Twenty-first Century: (New York: Palgrave Macmillan)

Review in New Genetics and Society here

Mittra, J & C. Milne (eds) (2013) Translational Medicine: The Future of Therapy?, (Singapore: Pan-Stanford)

Journal Articles

Mittra, J., Bruce, A., Scannell, Jack W., and Tait, J. (2021) ‘The Role of the Regulatory System in Supporting Innovation Pathways for the Development of New Antimicrobial Drugs’, Technology Analysis and Strategic Management, 33 (3) 283-295

Mastroeni, M., Mittra, J., and Tait, J (2021) 'Political Influences on Biotechnology-based Innovation for European Agriculture: Risk-Assessment and Risk Management', Technology Analysis and Strategic Management, 33 (3): 271-282

Banda, G; Mittra,J., et al. (2021) 'Understanding the emergence and evolution of new business models in the UK regnerative medicine sector', Technology Analysis and Strategic Management, 33 (3): 320-333

Mittra, J., and Zoukas, G. (2020) ‘Unpacking the Concept of Bioeconomy: Problems of Definition, Measurement and the Attribution of Value’, Science and Technology Studies, 33 (1): 2-21

Mittra, J., Mastroeni, M., Haddow, G., Wield, D., and Barlow, E. (2019) ‘Re-imagining Healthcare and Medical Research Systems in Post Devolution Scotland’, Sociological Research Online, 24 (1): 55-72

Banda, G;, Tait, J;, and Mittra, J. (2018) 'Evolution of Business Models in Regenerative Medicine: Effects of a Disruptive Innovation on the Innovation Ecosystem', Clinical Therapeutics, 40 (7): 1084-1094

Wield, D., Tait., J., Chataway, J., Mittra, J., and Mastroeni, M. (2017) ‘Conceptualising and practising multiple knowledge interactions in the life sciences’, Technological Forecasting and Social Change, 116, pp. 308-315

Milne, C-P., Mittra, J., Kojima, N., Sugiyama, D., Awatin, J., and Simmons, G. (2016) 'Prospects for Harmonizing Regulatory Science Programs in Europe, Japan, and the United States to Advance Regenerative Medicine', Therapeutic Innovation and Regulatory Science, 50 (6): 724-733

Mittra. J., J. Tait., M. Mastroeni., M. Turner., J. Mountford., K. Bruce. (2015) ‘Identifying Viable Regulatory and Innovation Pathways for Regenerative Medicine: A Case Study of Cultured Red Blood Cells', New Biotechnology, 32 (1): 180-190

Mittra, J. (2013) ‘Repairing the ‘Broken Middle’ of the Health Innovation Pathway: Exploring Diverse Practitioner Perspectives on the Emergence and Role of ‘Translational Medicine’, Science and Technology Studies, 26 (3)

Wield, D., R. Hanlin, J. Mittra & J. Smith (2013) ‘Twenty-First Century Bioeconomy: Global Challenges of Biological Knowledge for Health and Agriculture’, Science and Public Policy, 40, pp. 17-24

Mittra, J & J. Tait (2012) ‘Analysing Stratified Medicine Business Models and Value Systems: Innovation-Regulation Interactions’, New Biotechnology, 29 (6), pp. 709-719

Mittra, J., J. Tait & D. Wield (2011) ‘From Maturity to High Value-Added Innovation : Lessons from the Pharmaceutical and Agro-Biotechnology Industries’, Trends in Biotechnology, 29 (3), pp. 105-109

Mittra, J., J. Tait & D. Wield (2011) ‘The Future of Pharmaceutical Innovation: New Challenges and Opportunities’, Innovations in Pharmaceutical Technology, March 2011, pp. 32-34

Mittra, J. (2008) ‘Impact of the Life Sciences on Organisation and Management of R&D in Large Pharmaceutical Firms’, Int. J. Biotechnology, 10 (5), pp. 416-440

Mittra, J. (2007) ‘Predictive Genetic Information and Access to Life Assurance: The Poverty of Genetic Exceptionalism’, Biosocieties, 2 (3), pp. 349-373

Mittra, J. (2007) ‘Marginalising Eugenic Anxiety through a Rhetoric of Liberal Choice: A Critique of the House of Commons Select Committee Report on Reproductive Technologies’, New Genetics and Society, 26 (2), pp. 159-179

Mittra, J. (2007) ‘Life Science Innovation and the Re-structuring of the Pharmaceutical Industry: Merger, Acquisitions and Strategic Alliance Behaviour of Large Firms', Technology Analysis and Strategic Management, 19 (3), pp. 279-301

Mittra, J. & R. Williams (2007) ‘Evolution of the Life Science Industries’, Technology Analysis and Strategic Management, Special Issue, 19 (3), pp. 251-255

Mittra, J. (2006) ‘The Socio-Political Economy of Pharmaceutical Mergers: A Case study of Sanofi and Aventis', Technology Analysis and Strategic Management, 18 (5), pp. 473-496

Mittra, J. (2006) ‘Genetic Exceptionalism and Precautionary Politics: Regulating for Uncertainty in Britain's Genetics and Insurance Policy Process', Science and Public Policy, 33 (8) pp. 585-600

Book Chapters

Gardner, J., Webster, A., and Mittra, J. (2017) ‘ The ‘Entrepreneurial State’ and the Leveraging of Life in the Field of Regenerative Medicine’, in Pavone, P., and Goven. J (eds) Bioeconomies: Life, Technology and Capital in the 21st Century, (Basingstoke: Palgrave Macmillan)

Milne, C.P, & J. Mittra. (2015) ‘Is Translational Medicine the Future of Therapy?’, in R. Bawa (Editor), G. F. Audette and B. E. Reese. (Assistant Editors): Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk, Pan Stanford Publishing, Singapore, pp. 997-1012

Mittra, J (2013) ‘Exploiting Translational Medicine through Public-Private Partnerships: a Case Study of Scotland’s Translational Medicine Research Collaboration (TMRC)’, In Mittra & Milne (eds) Translational Medicine: The Future of Therapy? 2013, Pan-Stanford: Singapore, pp. 213-229

Mittra, J. & C. Milne (2013) ‘Introduction to Translational Medicine’, in Mittra & Milne (eds) Translational Medicine: The Future of Therapy? 2013, Pan-Stanford: Singapore, pp. 3-13

Reports

Tait, J., Bruce, A., Mittra, J., Purves, J., and Scannell, J. (2014) Independent Review on Antimicrobial Resistance: Regulation-Innovation Interactions and the Development of Antimicrobial Drugs and Diagnostics for Human and Animal Diseases, Main Report for ESRC Innogen Institute

Mittra, J., M. Mastroeni & J. Tait (2014) Engaging with Uncertainty and Risk in Agricultural Biotechnology Regulation: Delivering Safety and Innovation, Final Report of ESRC/Syngenta Knowledge Exchange Project

Omidvar, O., M. De Grijs., D. Castle, J. Mittra., A. Rosiello and J. Tait (2014) Regenerative Medicine: Business Models, Venture Capital and the Funding Gap, Report on ESRC Project, ‘New Funding Models for Regenerative Medicine’ ESRC Innogen Centre/Innogen Institute

Mastroeni, M., J. Mittra & J. Tait (2012) Methodology for the Analysis of Life Science Innovation Systems (ALSIS) and its Application to Three Case Studies, Final Report of the Technology Strategy Board (TSB) Project REALISE, May 2012

Mittra, J., & Tait, J. (2009) ‘Stem Cells’, chapter for RiskBridge Report, SAS6-CT-2006-036661, pp. 224-268

Mittra, J (2009) ‘Risk Governance and Policy Learning Within and Between Risk Fields‘, Proceedings of the RiskBridge Final Conference ECFP6 Coordination Action

Refereed Working Papers

Mittra, J., M. Mastroeni., D. Wield., E. Barlow and K. Snowden (2014) ‘The Scottish Institutional Ecology of Health and Clinical/Medical Research and Key Issues for Scottish Independence’, Innogen Working Paper Number 109,

Haddow, G., J. Mittra., K. Snowden., E. Barlow and D. Wield (2014) ‘From “Sick Man” to “Living Lab”: The Narrative of Scottish Health Since Devolution’, Innogen Working Paper, Number 108, Series ESRC Future of the UK and Scotland.

Mastroeni, M., E. Barlow., J. Mittra., and D. Wield (2014) ‘The Imagined Health Community: Narratives of Scottish Health and Independence’, Innogen Working Paper, Number 112,

Yoruk, D. and Mittra, J. (2009) 'Mid Pharma: How Big is it and Where is it Going?, Innogen Working paper 81

Mittra, J (2003) ‘Innovation Processes in Genomics Industry Sectors’, Innogen Working Paper 548

Policy Briefs/Consultation Responses

Mittra. J., E. Barlow., M. Mastroeni., D. Wield., G. Haddow (2014) ‘The Implications of Scottish Independence for Healthcare and Medical Research’, Innogen Briefing Number 2, August 2014, Series ESRC Future of the UK and Scotland.

Mittra., J (2009) Innogen Response to Human Genetics Commission Enquiry into Direct to Consumer Genetic Tests, October 2009:

Mittra, J. (2009) Response to Nuffield Council Consultation Paper: Medical Profiling and Online Medicine: the ethics of healthcare in the molecular age, July 2009,

Mittra, J (2007) ‘Appropriate Governance of the Life Sciences: Regulation and Risk Governance of Stem Cell Therapies’, Innogen policy brief

Mittra, J. (2007) ‘Changing Strategies of Big Pharma’, Innogen Policy Brief

Tait, J, Mittra, J (2004) ‘Complexity and Innovation in the Pharmaceutical Industry’, Innogen policy brief

Other Publications

Mittra, J., G. Haddow and M. Mastroeni (2014) ‘Is Scottish Independence Bad for your Health?’ The Conversation, 12 August, 2014,

Mittra, J. (2009) ‘Translating Translational Medicine’, The Gen: The Newsletter of the ESRC Genomics Network, issue 10, p16-17.

Mittra, J. (2007) ‘GlaxoSmithKline and the Reorganization of R&D’, Innogen Case Study Prepared for Executive Development Programme, 25-27 April 2007

Mittra, J. (2007) ‘Herceptin and the Politics of Drug Regulation’, Innogen Case Study Prepared for Executive Development Programme, 25-27 April 2007

Tait, J., and Mittra, J. (2006) ‘Singing from the same Hymn Sheet: Can Genomics Harmonise with Chemistry?’ CHEManager, August, 2006, p. 14

Mittra, J. (2005) ‘Pharmaceutical Industries: Do They Prefer Treatment to Cure?’ The Biochemist 27 (3): 32-34

Tait, J. & Mittra. J. (2005) ‘Big Pharma: Coping with Complexity’, ESRC Genomics Network Newsletter, Issue 2, June 2005

Tait, J. & Mittra, J. (2004) ’Industry Challenges’, Chemistry and Industry, 6 December, 2004, No. 23, p. 24

Mittra, J. & J. Sulston (2004) ‘Genetics and Insurance: Should We Legislate?’ Genomics Network Newsletter, Issue 1, September 2004: 9-12